Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer
Objective Precision oncology depends on translating molecular data into therapy recommendations. However, with the growing complexity of next-generation sequencing-based tests, clinical interpretation of somatic genomic mutations has evolved into a formidable task. Here, we compared the performance...
Main Authors: | Harry J M Groen, Qing Zhou, Ellen Heitzer, Michael R Speicher, Ed Schuuring, Samantha O Perakis, Sabrina Weber, Ricarda Graf, Sabine Hojas, Jakob M Riedl, Armin Gerger, Nadia Dandachi, Marija Balic, Gerald Hoefler, Jochen B Geigl |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-10-01
|
Series: | ESMO Open |
Online Access: | https://esmoopen.bmj.com/content/5/5/e000872.full |
Similar Items
-
Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer
by: Qing Zhou, et al.
Published: (2020-02-01) -
Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.
by: Sumitra Mohan, et al.
Published: (2014-03-01) -
Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer
by: Peter Ulz, et al.
Published: (2016-06-01) -
Longitudinal tumor fraction trajectories predict risk of progression in metastatic HR+ breast cancer patients undergoing CDK4/6 treatment
by: Nadia Dandachi, et al.
Published: (2021-09-01) -
Emerging concepts in liquid biopsies
by: Samantha Perakis, et al.
Published: (2017-04-01)